EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Repeated COVID‐19 vaccination to maximum antibody response yields very low mortality and hospitalisation rates in patients with CLL and MBL

Yandong Shen iD, Jane A Freeman iD, Ian Kerridge iD, Paul Downe, Kartik Naidu, Juliette Holland, Stephen P Mulligan iD

British Journal of Haematology · 2024

DOI: 10.1111/bjh.19087 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, 2024. Verfasst von Yandong Shen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology, Royal North Shore Hospital, St Leonards, New South Wales, Australia. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Lymphocytosis, COVID-19, Vaccines. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We analysed COVID‐19 infection outcomes of 129/241 chronic lymphocytic leukaemia (CLL) (53.9%) and 22/55 monoclonal B‐lymphocytosis (MBL) (40.0%) patients following multiple vaccine doses aiming for maximum measured anti‐spike antibody response. Throughout the pandemic to date, there were 8/129 CLL (6.2%) patients hospitalised, with one death (0.8%). No MBL patients were hospitalised or died. CLL patients with COVID‐19 had lower anti‐spike levels (3778.8 AU/mL) than those without (13 486.8 AU/mL; p = 0.0061). Anti‐nucleocapsid antibody was detected in 29.8% within 2 months and 17.5% >6 months. Of COVID‐19‐infected CLL patients, 47.3% received anti‐viral therapy. A multiple vaccine dosing strategy to achieve measured maximum antibody is highly effective in preventing severe COVID‐19.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Lymphocytic, Chronic, B-CellLymphocytosisCOVID-19VaccinesHumansB-LymphocytesCOVID-19 VaccinesAntibody FormationVaccination

Stichwörter der Autor:innen

CLLCOVID infection outcomeMBLmaximum antibody responsemultiple vaccination

Substanzen

COVID-19 VaccinesVaccines

Autor:innen und Institutionen

  • Department of Haematology, Royal North Shore Hospital, St Leonards, New South Wales, Australia.
  • Kolling Institute, Royal North Shore Hospital, University of Sydney, St Leonards, New South Wales, Australia.
  • Department of Haematology and Flow Cytometry, Healius Laverty Pathology, Macquarie Park, New South Wales, Australia.
  • Northern Haematology and Oncology Group, Sydney Adventist Hospital, Wahroonga, New South Wales, Australia.
  • Department of Microbiology, Healius Laverty Pathology, Macquarie Park, New South Wales, Australia.

ORCID-Profile: Yandong Shen, Jane A Freeman, Ian Kerridge, Stephen P Mulligan

Zitieren

APA

Shen, Y., Freeman, J. A., Kerridge, I., Downe, P., Naidu, K., Holland, J., & Mulligan, S. P. (2024). Repeated COVID‐19 vaccination to maximum antibody response yields very low mortality and hospitalisation rates in patients with CLL and MBL. British Journal of Haematology. https://doi.org/10.1111/bjh.19087

Vancouver

Shen Y, Freeman JA, Kerridge I, Downe P, Naidu K, Holland J, et al. Repeated COVID‐19 vaccination to maximum antibody response yields very low mortality and hospitalisation rates in patients with CLL and MBL. British Journal of Haematology. 2024. doi:10.1111/bjh.19087

BibTeX
@article{Shen2024,
  author = {Shen, Yandong and Freeman, Jane A and Kerridge, Ian and Downe, Paul and Naidu, Kartik and Holland, Juliette and Mulligan, Stephen P},
  title = {Repeated COVID‐19 vaccination to maximum antibody response yields very low mortality and hospitalisation rates in patients with CLL and MBL},
  journal = {British Journal of Haematology},
  year = {2024},
  doi = {10.1111/bjh.19087}
}
Kostenlos starten →